AstraZeneca's investment in research and development is paying off but market is yet to fully recognise its potential, says investment bankProactive Investors • 10/11/21
Coronavirus Update: Merck seeks authorization for what would be first pill to treat COVID-19, and AstraZeneca reports positive results for antibody treatmentMarket Watch • 10/11/21
AstraZeneca says its COVID-19 drug cuts the risk of severe disease in half. It's the first antibody cocktail shown to both prevent and treat the disease in late-stage trials.Business Insider • 10/11/21
AstraZeneca Says Drug Cocktail Effective in Reducing Risk of Developing Severe Covid-19Barrons • 10/11/21
AstraZeneca's Injectable Antibody Cocktail Halves Risk Of Death Or Developing Severe Covid, Trial FindsForbes • 10/11/21
AstraZeneca: Long-acting COVID antibody shown to prevent severe disease, deathMarket Watch • 10/11/21
AstraZeneca's experimental asthma gets an orphan drug designation for another diseaseMarket Watch • 10/08/21
AstraZeneca seeks emergency use authorisation for Covid-19 antibody drug in USProactive Investors • 10/05/21
AstraZeneca requests emergency authoritisation for drug that reduces risk of developing COVID symptoms by 77%Skynews • 10/05/21
AstraZeneca: FDA grants breakthrough-therapy designation for breast cancer drugMarket Watch • 10/04/21
AstraZeneca vaccine shows 74% efficacy in large Phase 3 trial in U.S., Chile and Peru: NJEMMarket Watch • 09/30/21
AstraZeneca (AZN) Up on Enhertu, Imfinzi Cancer Data at ESMO (Revised)Zacks Investment Research • 09/30/21